{"DataElement":{"publicId":"3171797","version":"1","preferredName":"Drug Abuse Type","preferredDefinition":"The listed types of illicit drugs used within the past year.","longName":"DRG_ABUSE_TYP","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"2728909","version":"1","preferredName":"Person Current Drug Abuse","preferredDefinition":"information related to the personal medical history (the reporting of medical events) of intravenous (within a blood vessel) drug abuse (the use of a drug for a reason other than which it was intended or in a manner or in quantities other than directed) in a person._Occurring in or belonging to the present time._The use of a drug for a reason other than which it was intended or in a manner or in quantities other than directed.","longName":"PERS_CURR_DRUG_ABUS","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2236731","version":"1","preferredName":"Person","preferredDefinition":"A human being.","longName":"C25190","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Person","conceptCode":"C25190","definition":"A human being.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FC6DF7-66EB-4CAB-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-20","endDate":null,"createdBy":"UMLLOADER_MAGE","dateCreated":"2005-06-20","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2728907","version":"1","preferredName":"Current Drug Abuse","preferredDefinition":"Occurring in or belonging to the present time.:The use of a drug for a reason other than which it was intended or in a manner or in quantities other than directed.","longName":"C25471:C16522","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Current","conceptCode":"C25471","definition":"Occurring in or belonging to the present time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Drug Abuse","conceptCode":"C16522","definition":"The use of a drug for a reason other than which it was intended or in a manner or in quantities other than directed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"460107F2-D61C-3611-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-02-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-02-12","modifiedBy":"ONEDATA","dateModified":"2008-02-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008566","version":"1","preferredName":"Behavior","preferredDefinition":"Observations and activities relating to behavior, such as smoking and ETOH use.\r\n","longName":"BEHAVIOR","context":"SPOREs","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B78145CC-5DBF-209B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-02-25","endDate":null,"createdBy":"MEDVEDOH","dateCreated":"2003-02-25","modifiedBy":"REEVESD","dateModified":"2004-11-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"460107F2-D62D-3611-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-02-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-02-12","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3171758","version":"1","preferredName":"Drug Abuse Type","preferredDefinition":"The listed types of abused drugs.","longName":"DRG_ABUSE_TYP","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2946060","version":"1","preferredName":"Other","longName":"2946060","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"746A8063-D650-3C9D-E040-BB89AD437A9B","latestVersionIndicator":"Yes","beginDate":"2009-09-25","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-25","modifiedBy":"GDEEN","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":"1/25/23 added alt name for ticket number CADSR0001948 for CCTG cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97DD4929-E137-C86E-E040-BB89AD432EF5","beginDate":"2010-12-20","endDate":null,"createdBy":"LUY","dateCreated":"2010-12-20","modifiedBy":"SBR","dateModified":"2018-12-20","deletedIndicator":"No"},{"value":"Opioids","valueDescription":"Opioid","ValueMeaning":{"publicId":"2944388","version":"1","preferredName":"Opioid","longName":"2944388","preferredDefinition":"A class of synthetic chemicals/drugs similar to opiates (opium derivatives) with analgesic properties.  Due to binding to opiate receptors, opioids mimic opiate activity on neurons, various cells (i.e. lymphocytes), pain suppression and other neurobehavioral activity. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Opioid","conceptCode":"C1506","definition":"A class of synthetic chemicals/drugs similar to opiates (opium derivatives) with analgesic properties.  Due to binding to opiate receptors, opioids mimic opiate activity on neurons, various cells (i.e. lymphocytes), pain suppression and other neurobehavioral activity. (NCI)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"74328713-0E80-E217-E040-BB89AD436CEF","latestVersionIndicator":"Yes","beginDate":"2009-09-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-09-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97DD4929-E14B-C86E-E040-BB89AD432EF5","beginDate":"2010-12-20","endDate":null,"createdBy":"LUY","dateCreated":"2010-12-20","modifiedBy":"SBR","dateModified":"2018-12-20","deletedIndicator":"No"},{"value":"Inhalants","valueDescription":"Inhalation","ValueMeaning":{"publicId":"3171759","version":"1","preferredName":"Inhalation","longName":"3171759","preferredDefinition":"In medicine, refers to the act of taking a substance into the body by breathing.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aspiration, CTCAE","conceptCode":"C28245","definition":"A disorder characterized by inhalation of solids or liquids into the lungs.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97DD4929-E155-C86E-E040-BB89AD432EF5","latestVersionIndicator":"Yes","beginDate":"2010-12-20","endDate":null,"createdBy":"LUY","dateCreated":"2010-12-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97DD4929-E16E-C86E-E040-BB89AD432EF5","beginDate":"2010-12-20","endDate":null,"createdBy":"LUY","dateCreated":"2010-12-20","modifiedBy":"SBR","dateModified":"2018-12-20","deletedIndicator":"No"},{"value":"Hallucinogens","valueDescription":"Hallucinogen Dependence","ValueMeaning":{"publicId":"3171761","version":"1","preferredName":"Hallucinogen Dependence","longName":"3171761","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hallucinogen Dependence","conceptCode":"C34657","definition":"A drug dependence for a hallucinogenic substance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97DD4929-E17B-C86E-E040-BB89AD432EF5","latestVersionIndicator":"Yes","beginDate":"2010-12-20","endDate":null,"createdBy":"LUY","dateCreated":"2010-12-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97DD4929-E194-C86E-E040-BB89AD432EF5","beginDate":"2010-12-20","endDate":null,"createdBy":"LUY","dateCreated":"2010-12-20","modifiedBy":"SBR","dateModified":"2018-12-20","deletedIndicator":"No"},{"value":"Cocaine","valueDescription":"Cocaine","ValueMeaning":{"publicId":"3171762","version":"1","preferredName":"Cocaine","longName":"3171762","preferredDefinition":"A tropane alkaloid with central nervous systems (CNS) stimulating and local anesthetic activity.  Cocaine binds to the dopamine, serotonin, and norepinephrine transport proteins and inhibits the re-uptake of dopamine, serotonin, and norepinephrine into pro-synaptic neurons.  This leads to an accumulation of the respective neurotransmitters in the synaptic cleft and may result in increased postsynaptic receptor activation.  The mechanism of action through which cocaine exerts its local anesthetic effects is by binding to and blocking the voltage-gated sodium channels in the neuronal cell membrane.  By stbilizing neuronal membranes, cocaine inhibits the initiation and conduction of nerve impulses and produces a reversible loss of sensation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cocaine","conceptCode":"C80153","definition":"A tropane alkaloid with central nervous systems (CNS) stimulating and local anesthetic activity. Cocaine binds to the dopamine, serotonin, and norepinephrine transport proteins and inhibits the re-uptake of dopamine, serotonin, and norepinephrine into pre-synaptic neurons. This leads to an accumulation of the respective neurotransmitters in the synaptic cleft and may result in increased postsynaptic receptor activation. The mechanism of action through which cocaine exerts its local anesthetic effects is by binding to and blocking the voltage-gated sodium channels in the neuronal cell membrane. By stabilizing neuronal membranes, cocaine inhibits the initiation and conduction of nerve impulses and produces a reversible loss of sensation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97DD4929-E19E-C86E-E040-BB89AD432EF5","latestVersionIndicator":"Yes","beginDate":"2010-12-20","endDate":null,"createdBy":"LUY","dateCreated":"2010-12-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97DD4929-E1B6-C86E-E040-BB89AD432EF5","beginDate":"2010-12-20","endDate":null,"createdBy":"LUY","dateCreated":"2010-12-20","modifiedBy":"SBR","dateModified":"2018-12-20","deletedIndicator":"No"},{"value":"Cannabis","valueDescription":"Marijuana","ValueMeaning":{"publicId":"2579325","version":"1","preferredName":"Marijuana","longName":"2579325","preferredDefinition":"Any part of, or extract from, the female hemp plant Cannabis sativa.  Marijuana contains cannabinoids, substances with hallucinogenic, psychoactive, and addictive properties.  This agent has potential use for treating cancer pain and cachexia. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Marijuana","conceptCode":"C26659","definition":"Any part of, or extract from, the female hemp plant Cannabis sativa.  Marijuana contains cannabinoids, substances with hallucinogenic, psychoactive, and addictive properties.  This agent has potential use for treating cancer pain and cachexia. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-02EA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-06-21","endDate":null,"createdBy":"SBR","dateCreated":"2004-06-21","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97DD4929-E1CA-C86E-E040-BB89AD432EF5","beginDate":"2010-12-20","endDate":null,"createdBy":"LUY","dateCreated":"2010-12-20","modifiedBy":"SBR","dateModified":"2018-12-20","deletedIndicator":"No"},{"value":"Amphetamines","valueDescription":"Amphetamine","ValueMeaning":{"publicId":"3171764","version":"1","preferredName":"Amphetamine","longName":"3171764","preferredDefinition":"A synthetic substance related to natural sympathomimetic amines. Amphetamine appears to exert its central nervous system (CNS) and peripheral effects indirectly by inducing the release of biogenic amines from their storage sites in nerve terminals. This agent is a commonly abused psychostimulant drug, which may be snorted, taken orally, smoked, or injected.  Amphetamine induces psychologic dependence which is manifested by elevated mood, increased wakefulness, concentration, physical performance and a feeling of well-being. With sustained use, the effects of tachycardia and enhanced alertness diminish while psychotoxic effects such as hallucinations and delusions may occur. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amphetamine","conceptCode":"C62006","definition":"A synthetic substance related to natural sympathomimetic amines. Amphetamine appears to exert its central nervous system (CNS) and peripheral effects indirectly by inducing the release of biogenic amines from their storage sites in nerve terminals. This agent is a commonly abused psychostimulant drug, which may be snorted, taken orally, smoked, or injected.  Amphetamine induces psychologic dependence which is manifested by elevated mood, increased wakefulness, concentration, physical performance and a feeling of well-being. With sustained use, the effects of tachycardia and enhanced alertness diminish while psychotoxic effects such as hallucinations and delusions may occur. (NCI04)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97DD4929-E1D7-C86E-E040-BB89AD432EF5","latestVersionIndicator":"Yes","beginDate":"2010-12-20","endDate":null,"createdBy":"LUY","dateCreated":"2010-12-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97DD4929-E1F0-C86E-E040-BB89AD432EF5","beginDate":"2010-12-20","endDate":null,"createdBy":"LUY","dateCreated":"2010-12-20","modifiedBy":"SBR","dateModified":"2018-12-20","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008566","version":"1","preferredName":"Behavior","preferredDefinition":"Observations and activities relating to behavior, such as smoking and ETOH use.\r\n","longName":"BEHAVIOR","context":"SPOREs","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B78145CC-5DBF-209B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-02-25","endDate":null,"createdBy":"MEDVEDOH","dateCreated":"2003-02-25","modifiedBy":"REEVESD","dateModified":"2004-11-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3171757","version":"1","preferredName":"Drug Abuse Type","preferredDefinition":"The use of a drug for a reason other than which it was intended or in a manner or in quantities other than directed.:Type; a subdivision of a particular kind of thing.","longName":"C16522:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Drug Abuse","conceptCode":"C16522","definition":"The use of a drug for a reason other than which it was intended or in a manner or in quantities other than directed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97DD4929-E112-C86E-E040-BB89AD432EF5","latestVersionIndicator":"Yes","beginDate":"2010-12-20","endDate":null,"createdBy":"LUY","dateCreated":"2010-12-20","modifiedBy":"ONEDATA","dateModified":"2010-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NINDS:National Institute of Neurological Disorders and Stroke Common Data Element Project","workflowStatus":"RELEASED","registrationStatus":"Application","id":"97DD4929-E123-C86E-E040-BB89AD432EF5","latestVersionIndicator":"Yes","beginDate":"2010-12-20","endDate":null,"createdBy":"LUY","dateCreated":"2010-12-20","modifiedBy":"SBR","dateModified":"2018-12-20","changeDescription":"5/29/18 - smt CDE transferred to NCIP ownership per NINDS (Muniza Sheikh) request.\r\n","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3896529","version":"1","longName":"Consortia 2012 Studies","context":"DCP","ClassificationSchemeItems":[{"publicId":"3694151","version":"1","longName":"MAY2012-00-01","context":"DCP"}]},{"publicId":"6272292","version":"1","longName":"NINDS","context":"NCIP","ClassificationSchemeItems":[{"publicId":"3145517","version":"1","longName":"Participant/Subject History and Family History","context":"NCIP"},{"publicId":"10000274","version":"1","longName":"General Health History","context":"NCIP"},{"publicId":"3145522","version":"1","longName":"Behavioral History at Baseline","context":"NCIP"}]}],"AlternateNames":[{"name":"DCP","type":"USED_BY","context":"DCP"}],"ReferenceDocuments":[{"name":"If yes, specify type(s)","type":"Preferred Question Text","description":"If yes, specify type(s)","url":null,"context":"NCIP"},{"name":"NINDS CDE Project","type":"REFERENCE","description":"NINDS CDE Project","url":"http://www.commondataelements.ninds.nih.gov/","context":"NCIP"},{"name":"Name","type":"Alternate Question Text","description":"Name","url":null,"context":"DCP"}],"origin":"NINDS:National Institute of Neurological Disorders and Stroke Common Data Element Project","workflowStatus":"RELEASED","registrationStatus":"Application","id":"97DD4929-E20C-C86E-E040-BB89AD432EF5","latestVersionIndicator":"Yes","beginDate":"2010-12-20","endDate":null,"createdBy":"LUY","dateCreated":"2010-12-20","modifiedBy":"SBR","dateModified":"2018-12-20","changeDescription":"5/25/18 - smt CDE transferred to NCIP ownership per NINDS (Muniza Sheikh) request.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}